Popular search terms:
Search Results
53 results found-
Abbreviation Term AE Adverse event AEFI Adverse event following immunization ART Antiretroviral therapy CAEFISS Canadian Adverse Events Following Immunization Surveillance System CI Confidence interval CIG Canadian Immunization Guide DIN Drug Identification Number FFU Fluorescent focus units GBS Guillain-Barré syndrome GMT Geometric mean titre GMTR Geometric mean titre ratio HA Hemagglutinin HAART Highly active antiretroviral therapy HCW Health care worker HIV Human immunodeficiency virus Ig Immunoglobulin IIV Inactivated influenza vaccine IIV3 Trivalent inactivated influenza vaccine IIV3-Adj Adjuvanted trivalent inactivated influenza vaccine (egg-based) IIV3-HD High-dose trivalent inactivated influenza vaccine (egg-based) IIV3-SD Standard-dose trivalent inactivated influenza vaccine (egg-based) IIV4 Quadrivalent inactivated influenza vaccine Mammalian cell culture-based quadrivalent inactivated influenza IIV4-cc vaccine IIV4-HD High-dose quadrivalent inactivated influenza vaccine (egg-based) IIV4-SD Standard-dose quadrivalent inactivated influenza vaccine (egg-based) ILI Influenza-like illness
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/naci-2022-2023-statement.pdf -
Higher Dose and Adjuvanted Influenza Vaccines for Persons 65yr+
https://www.seqirus.ca/-/media/seqirus-canada/docs-fr/2022-references-fr.pdf -
Higher Dose and Adjuvanted Influenza Vaccines for Persons 65yr+ https://www.cdc.gov/vaccines/acip/recs/grade/influenza-older-adults.html SREF-15734 14.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2022-references-en.pdf -
Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinin of influenza virus strains representing the influenza viruses likely to circulate in Canada in the upcoming winter on the basis of the recommendations from the World Health Organization (WHO) and the National Advisory Committee on Immunization (NACI).
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/flucelvax-product-monograph---asu-2022-23---en-final-approved-05-may-2022.pdf -
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Amongamong Healthcare Personnel Aged 18-64 Years:
https://www.seqirus.ca/-/media/seqirus-canada/docs-fr/naci-2022-2023-statement-fr.pdf -
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2022-2023-fluad-product-monograph.pdf -
Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults
https://www.seqirus.ca/news/canadian-surveys-highlight-flu-ed-with-healthcare-pros-ease-of-access-critical-vaccination-uptake -
9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/afluria-product-monograph---asu-2022-23---en-final-approved-12-may-2022.pdf -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.seqirus.ca/ -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.seqirus.ca/our-company